OCC Trading, page-1425

That's right, @Stockcount - the next quarterly report is indeed coming up - in just over two weeks.

It's still early days, of course, so I'm not expecting anything huge, but I do expect to see revenue figures moving in the right direction. (Given that we don't know the exact timing of payments we are more likely to get a better idea of progress over several quarters.)

In any case, we might get other information as well. In the Half Yearly Report released 28th of February covering the 6 months to 31st December, it was stated: "First orders of Remplir were shipped to DVT on September 22 and an additional order was received and shipped during the period."

It will be really interesting to see the rate at which Remplir is taken up by surgeons in the Australian market because it should give us a good indication of how things will go in the much larger US market later on. (It will also provide invaluable information when negotiating any future deals.)

I don't know what others think, but it seems to me that Remplir is the next big thing for Orthocell. Why would any surgeon not want to use what appears to be the best available product for repairing damaged nerves - producing the best and quickest results? Since Remplir was added to the Australian Prothesis List - thereby reducing the cost of surgery to patients - I think patients will be demanding that it's used anyway. (So long as they know about it - but that's the job of marketing.)

Something else I guess we will all be looking out for is further news concerning entry into the US market. It was stated in the half yearly report: "The company continues to work closely with US regulatory advisors, to evaluate opportunities for expedited approval of Remplir for nerve regeneration and is on track to commence the comparator animal study 510K in Q1 CY 2023."

Well, I won't be too fussed if it's not announced precisely in this quarter so long as it comes along soon. I can imagine the recent high-profile appointments (of Nerve Surgeons no less) might mean that some refining to the 510K application is underway. We shall see. What matters to me is they get it right.

@Stockcount's last post concluded: "Every quarter is a step closer to great success." You bet! There seems to be something inevitable about Orthocell's progress - like a massive freight train gradually building up speed - it takes a while, but once it gets going, there ain't nothing can to stop it!